Adapalene - CAS 106685-40-9
Catalog number: 106685-40-9
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C28H28O3
Molecular Weight:
412.52
COA:
Inquire
Targets:
RAR/RXR
Description:
Adapalene is more active than indomethacin, betamethasone valerate, tretinoin, isotretinoin or etretinate in inhibiting lipoxygease activity, but it has little activity against cyclo-oxygenase.
Purity:
>98%
Synonyms:
CD-271
MSDS:
Inquire
InChIKey:
LZCDAPDGXCYOEH-UHFFFAOYSA-N
InChI:
InChI=1S/C28H28O3/c1-31-26-7-6-23(21-2-3-22-12-24(27(29)30)5-4-20(22)11-21)13-25(26)28-14-17-8-18(15-28)10-19(9-17)16-28/h2-7,11-13,17-19H,8-10,14-16H2,1H3,(H,29,30)
Canonical SMILES:
COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5
1.Recent advances in the use of adapalene 0.1%/benzoyl peroxide 2.5% to treat patients with moderate to severe acne.
Leyden J1. J Dermatolog Treat. 2016 Mar;27 Suppl 1:S4-S13. doi: 10.3109/09546634.2016.1145338.
The central role of inflammation in acne is now more clearly understood. Adapalene, a third-generation topical retinoid, down-regulates toll-like receptor 2 expression and inhibits activator protein-1 activity. In a fixed-dose combination, adapalene and benzoyl peroxide (BPO) act synergistically on inflammatory patterns through regulation of innate immunity. In addition to reducing inflammatory and non-inflammatory lesions, adapalene/BPO helps prevent lesion and microcomedone formation. The combination of a topical retinoid and antimicrobial agent remains the preferred approach for almost all patients with acne. In cases of more severe disease, there is a clinical benefit in combining adapalene/BPO with an oral antibiotic for 12 weeks. Most recently, adapalene/BPO plus doxycycline 200 mg was found to be highly effective when compared with isotretinoin in the treatment of patients with severe acne with nodules. Long-term maintenance therapy is needed for most patients.
2.Customized Single-agent Therapy Management of Severe Inflammatory Acne: A Randomized, Double-blind, Parallel-group, Controlled Study of a New Treatment--Adapalene 0.3%-Benzoyl Peroxide 2.5% Gel.
Weiss J, Stein Gold L, Leoni M, Rueda MJ, Liu H, Tanghetti E. J Drugs Dermatol. 2015 Dec;14(12):1427-35.
BACKGROUND: More effective therapies are needed in the specific treatment of severe inflammatory acne vulgaris.
3.Accelerated Onset of Action and Increased Tolerability in Treating Acne With a Fixed-Dose Combination Gel.
Friedman A, Waite K, Brandt S, Meckfessel MH. J Drugs Dermatol. 2016 Feb 1;15(2):231-6.
Nonadherence to topical acne therapies is a major contributing factor to poor treatment outcomes. Multiple contributing factors have been identified, including a lack of perceived efficacy and fear of side effects. A fixed-dose combination gel of adapalene/benzoyl peroxide gel, 0.1%/2.5% (A-BPO) is an efficacious and safe treatment for a range of acne severities in patients as young as 9 years old. A meta-analysis of 14 clinical studies involving A-BPO was conducted to assess the 4 week efficacy and overall tolerability of this treatment. Over 2,300 subjects were included in the analysis. Mean total, inflammatory, and non-inflammatory lesion counts decreased at 4 weeks by 40.8%, 46.2%, and 37.5%, respectively. Worst post-baseline tolerability scores for stinging/burning, dryness, scaling, and erythema were none or mild for a majority of subjects. The result of this meta-analysis add to the body of literature supporting the use of A-BPO in a variety of acne patients and shows that A-BPO provides meaningful clinical results within 4 weeks and will be well-tolerated for a majority of patients.
4.Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study.
Stein Gold L1,2, Weiss J3, Rueda MJ4, Liu H5, Tanghetti E6. Am J Clin Dermatol. 2016 Mar 5. [Epub ahead of print]
BACKGROUND: A need exists for topical treatments in managing more severe inflammatory acne.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related RAR/RXR Products


CAS 153559-49-0 Bexarotene

Bexarotene
(CAS: 153559-49-0)

Bexarotene is a retinoid specifically selective for retinoid X receptors, used as an oral antineoplastic agent in the treatment of cutaneous T-cell lymphoma.

CAS 106685-40-9 Adapalene

Adapalene
(CAS: 106685-40-9)

Adapalene is more active than indomethacin, betamethasone valerate, tretinoin, isotretinoin or etretinate in inhibiting lipoxygease activity, but it has little ...

CAS 262433-54-5 BMS 270394

BMS 270394
(CAS: 262433-54-5)

BMS 270394 is a nuclear retinoic acid receptor (RAR-γ) agonist.

CAS 1190848-23-7 Fluorobexarotene

Fluorobexarotene
(CAS: 1190848-23-7)

Fluorobexarotene is a RXR agonist (Ki = 12 nM; EC50 = 43 nM at RXRα receptors).

CAS 185629-22-5 BMS 961

BMS 961
(CAS: 185629-22-5)

BMS 961 is a potent and selective RARγ agonist (EC50 = 30 and 1000 nM at RARγ and RARβ, respectively) displaying no activity at RARα receptors. It was found tha...

CAS 870773-76-5 AC 261066

AC 261066
(CAS: 870773-76-5)

AC 261066 is a potent RARβ2 agonist (pEC50 = 8.1).

CAS 155877-83-1 LE 135

LE 135
(CAS: 155877-83-1)

LE 135 is a retinoic acid antagonist which shows moderate selectivity for RARβ over RARα. It can inhibit human HL-60 leukemia cell differentiation induced by Am...

CAS 215307-86-1 BMS 753

BMS 753
(CAS: 215307-86-1)

BMS 753 is a RARα-selective agonist (Ki = 2 nM) that modulates the ATRA-inducible cytochrome P450 26A1 (CYP26A1).

Chemical Structure

CAS 106685-40-9 Adapalene

Quick Inquiry

Verification code

Featured Items